Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?

The company has great potential if and when it enters the commercial stage.

C : 59.33 (-1.49%)
EDIT : 5.06 (-7.83%)
Editas: Q1 Earnings Snapshot

Editas: Q1 Earnings Snapshot

EDIT : 5.06 (-7.83%)
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

The company now has a chance to get its lead program out the door a bit sooner.

C : 59.33 (-1.49%)
EDIT : 5.06 (-7.83%)
1 Beaten-Down Stock With 55% Upside, According to Wall Street

The biotech has bounced back some in the past year.

EDIT : 5.06 (-7.83%)
Why Editas Medicine Stock Soared as Much as 42% Higher This Week

The clinical-stage genome editing company dropped a couple of important announcements for shareholders.

VRTX : 480.73 (+0.35%)
C : 59.33 (-1.49%)
EDIT : 5.06 (-7.83%)
Editas: Q4 Earnings Snapshot

Editas: Q4 Earnings Snapshot

EDIT : 5.06 (-7.83%)
2 Under-the-Radar Stocks With Incredible Upside Potential

It's also important to consider their downsides.

EDIT : 5.06 (-7.83%)
RXRX : 9.26 (-1.91%)
Could Editas Medicine Become the Next CRISPR Therapeutics?

The similarities between the pair are striking, but it might not be enough.

EDIT : 5.06 (-7.83%)
CRSP : 63.56 (-2.60%)
Down 88%, Could Editas Medicine Be a Good Investment Now?

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

VRTX : 480.73 (+0.35%)
CRSP : 63.56 (-2.60%)
EDIT : 5.06 (-7.83%)
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

These two are at very different stages of the clinical trials process.

EDIT : 5.06 (-7.83%)
NTLA : 25.15 (-3.12%)

Barchart Exclusives

3 Highest-yielding Tech Stocks to Buy Now
Tech stocks aren't famous for paying dividends. There are, however, a select few that do. Here are the top 3 based on yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar